» Articles » PMID: 36720737

Development and External Validation of a Radiomics Model for Assessment of HER2 Positivity in Men and Women Presenting with Gastric Cancer

Overview
Publisher Springer
Specialty Radiology
Date 2023 Jan 31
PMID 36720737
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To develop and externally validate a conventional CT-based radiomics model for identifying HER2-positive status in gastric cancer (GC).

Methods: 950 GC patients who underwent pretreatment CT were retrospectively enrolled and assigned into a training cohort (n = 388, conventional CT), an internal validation cohort (n = 325, conventional CT) and an external validation cohort (n = 237, dual-energy CT, DECT). Radiomics features were extracted from venous phase images to construct the "Radscore". On the basis of univariate and multivariate analyses, a conventional CT-based radiomics model was built in the training cohort, combining significant clinical-laboratory characteristics and Radscore. The model was assessed and validated regarding its diagnostic effectiveness and clinical practicability using AUC and decision curve analysis, respectively.

Results: Location, clinical TNM staging, CEA, CA199, and Radscore were independent predictors of HER2 status (all p < 0.05). Integrating these five indicators, the proposed model exerted a favorable diagnostic performance with AUCs of 0.732 (95%CI 0.683-0.781), 0.703 (95%CI 0.624-0.783), and 0.711 (95%CI 0.625-0.798) observed for the training, internal validation, and external validation cohorts, respectively. Meanwhile, the model would offer more net benefits than the default simple schemes and its performance was not affected by the age, gender, location, immunohistochemistry results, and type of tissue for confirmation (all p > 0.05).

Conclusions: The conventional CT-based radiomics model had a good diagnostic performance of HER2 positivity in GC and the potential to generalize to DECT, which is beneficial to simplify clinical workflow and help clinicians initially identify potential candidates who might benefit from HER2-targeted therapy.

Citing Articles

Overlooked and underpowered: a meta-research addressing sample size in radiomics prediction models for binary outcomes.

Zhong J, Liu X, Lu J, Yang J, Zhang G, Mao S Eur Radiol. 2025; 35(3):1146-1156.

PMID: 39789271 PMC: 11835977. DOI: 10.1007/s00330-024-11331-0.


Hepatoid adenocarcinoma of the stomach: discrimination from conventional gastric adenocarcinoma with a computed tomography-based radiomics nomogram.

Gu X, Rong J, Zhu L, Dai Z, Ren S, Chen J J Gastrointest Oncol. 2024; 15(5):2041-2052.

PMID: 39554578 PMC: 11565099. DOI: 10.21037/jgo-24-210.


A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study.

Wei Z, Bai X, Xv Y, Chen S, Yin S, Li Y Insights Imaging. 2024; 15(1):262.

PMID: 39466475 PMC: 11519251. DOI: 10.1186/s13244-024-01840-3.


Contrast-enhanced computed tomography-based radiomics nomogram for predicting HER2 status in urothelial bladder carcinoma.

Peng J, Tang Z, Li T, Pan X, Feng L, Long L Front Oncol. 2024; 14:1427122.

PMID: 39206159 PMC: 11349509. DOI: 10.3389/fonc.2024.1427122.

References
1.
. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2020; 24(1):1-21. PMC: 7790804. DOI: 10.1007/s10120-020-01042-y. View

2.
Park J, Lee N, Beom S, Kim H, Lee C, Rha S . The prognostic value of volume-based parameters using F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2017; 21(2):213-224. DOI: 10.1007/s10120-017-0739-0. View

3.
Chen R, Zhou X, Liu J, Huang G . Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. J Nucl Med. 2016; 57(7):1040-4. DOI: 10.2967/jnumed.115.171165. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Wang Y, Yu Y, Han W, Zhang Y, Jiang L, Xue H . CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. Acad Radiol. 2020; 28(3):e86-e92. DOI: 10.1016/j.acra.2020.02.018. View